Status:
COMPLETED
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
30-75 years
Phase:
PHASE3
Brief Summary
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus usi...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes, but otherwise healthy
- HbA1c between 6.6% and 9.5%, inclusive.
- Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.
- Treated with a stable dose of metformin for at least 2 months prior to screening.
Exclusion
- Patients previously in a study using exenatide.
- Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening).
- Treated with insulin within 3 months of screening.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00097500
Start Date
September 1 2004
End Date
December 1 2009
Last Update
April 7 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Helsinki, Finland
2
Research Site
Amsterdam, Netherlands
3
Research Site
Gothenburg, Sweden